Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA653
  • Published: 
Download guidance (PDF)

2 Information about osimertinib

Marketing authorisation indication

2.1

Osimertinib (Tagrisso, AstraZeneca) has a marketing authorisation for 'the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC)'.

Dosage in the marketing authorisation

Price

2.3

The price for 30 tablets (either 40 mg or 80 mg) is £5,770 (BNF online, accessed February 2020). The company has a commercial arrangement that makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.